SY001 / CellOrigin Biotech - LARVOL DELTA

CellOrigin announced treatment of the first patient with CAR-M in China and reported the second generation of CAR-M for solid tumors (PRNewswire) - P=NA | N=02 | "Recently, a CAR-macrophage therapy product (CAR-M) SY001 from CellOrigin Biotechnology (Hangzhou) Co., Ltd. was dosed to the first patient in a hospital in China....The successful completion of the first patient dosing of SY001 demonstrates the advanced technology of the company's R&D platform and the maturity of the CMC platform. Currently, the clinical study is actively recruiting patients....SY001 was well tolerated and no dose-limiting toxicity (DLT) was observed (n=2). Only 2 grade 3 adverse events occurred; Common grade 1 - 2 adverse events included fever, elevated C-reactive protein, etc. No cytokine release syndrome or neurotoxicity related to cell infusion occurred in any patients."

Clinical data • Trial status • Oncology • Solid Tumor